abstract |
The present invention relates to antagonists of corticotropin releasing factor (CRF) of formula (1) and their use for the treatment of disorders caused or amplified by CRF, anxiety, depression and other mental, neurological disorders, as well as in the treatment of immunological, cardiovascular or heart-related diseases and hypersensitivity (allergy) of the colon associated with psychopathological disorder and stress. |